Nusano Announces Series C Financing of Over $115M to Commercialize RadioisotopesFunding supports development and commercialization of broad array of isotopes for medical, commercial and industrial usesVALENCIA, Calif., October 1, 2024-- Nusano, Inc., a physics company transforming the production of radioisotopes, today announced a Series C financing round with funding commitments of over $115 million in total proceeds.

Nusano宣布C系列融资超过1.15亿美元，用于放射性同位素商业化。资金支持用于医疗、商业和工业用途的多种同位素的开发和商业化。加利福尼亚州瓦伦西亚，2024年10月1日——Nusano，Inc.，一家改造放射性同位素生产的物理公司，今天宣布了一轮C系列融资，总收益超过1.15亿美元。

The financing will support the company’s initial product launches of non-carrier-added lutetium-177 (n.c.a. Lu-177) and actinium-225 (Ac-225)..

该融资将支持该公司首次推出非载体添加的镥-177（n.c.a.Lu-177）和锕-225（Ac-225）产品。。

The round was led by The Wasatch Group, with additional participation by S32. Previous investors in Nusano include Verily and the American Cancer Society’s BrightEdge.

这一轮由瓦萨奇小组领导，S32也参加了。Nusano之前的投资者包括Verily和美国癌症协会的BrightEdge。

“This financing supports our work to stabilize radiopharmaceutical supply chains and enable innovation across a variety of industries, including aerospace, industrial and long-lived power supplies,” said Chris Lowe, CEO of Nusano. “We look forward to bringing new radioisotope supplies online starting in 2025 and the role Nusano will play in making a greater variety of radioisotopes – such as astatine, copper, iridium and scandium – available for multiple markets.”.

Nusano首席执行官克里斯·洛（ChrisLowe）表示：“这笔资金支持我们稳定放射性药物供应链的工作，并实现包括航空航天、工业和长寿命电源在内的多种行业的创新。”。“我们期待着从2025年开始在线提供新的放射性同位素供应，努萨诺将发挥作用，为多个市场提供更多种类的放射性同位素，如阿斯汀、铜、铱和钪。”。

Radioisotopes are essential components in the active pharmaceutical ingredients (APIs) used in a category of new and emerging cancer therapies. Existing supply chains for these treatment-enabling resources are often strained, posing a risk to patient care and ongoing drug development.

。这些治疗支持资源的现有供应链往往紧张，对患者护理和正在进行的药物开发构成风险。

Nusano is working to stabilize supply chains and enable innovation by bringing new sources of radioisotopes to medical and industrial markets. In 2025, the company will launch two breakthrough technologies poised to transform radioisotope supply availability: a proprietary separation process for high-volume n.c.a.

努萨诺正在努力稳定供应链，并通过将放射性同位素的新来源带入医疗和工业市场来实现创新。2025年，该公司将推出两项突破性技术，以改变放射性同位素供应的可用性：一种用于大容量n.c.a.的专有分离工艺。

Lu-177 production, and a first-of-its-kind radioisotope production platform..

Lu-177生产，以及同类放射性同位素生产平台中的第一个。。

High-Volume n.c.a. Lu-177

大容量n.c.a.Lu-177

The most in-demand isotope in radiotherapeutics today is n.c.a. Lu-177. Nusano has developed a proprietary isotope separation process to enable n.c.a. Lu-177 production on a scale far greater than existing methods. The company’s n.c.a. Lu-177 program is scheduled to begin Q1 2025 to supply current and anticipated medical needs..

今天放射治疗学中最需要的同位素是n.c.a.Lu-177。努萨诺开发了一种专有的同位素分离工艺，使n.c.a.Lu-177的生产规模远远超过现有方法。该公司的北卡罗来纳州Lu-177项目计划于2025年第一季度开始，以满足当前和预期的医疗需求。。

Nusano Production Platform

Nusano生产平台

Opening in 2025 in West Valley City, Utah, the Nusano production platform will support the company’s Ac-225 production and be capable of generating more than 25 radioisotopes applicable to medical and industrial uses. It is anchored by a proprietary ion source technology which accelerates heavy particles (alphas and deuterons) to generate high volume, high quality (cGMP-grade) radioisotopes with unparalleled efficiency using eco-friendly methods.

Nusano生产平台将于2025年在犹他州西谷市开放，将支持该公司的Ac-225生产，并能够产生超过25种适用于医疗和工业用途的放射性同位素。它由一种专有的离子源技术锚定，该技术可加速重粒子（α和氘核），使用环保方法以无与伦比的效率产生高容量，高质量（cGMP级）放射性同位素。

The result is one of the first significant advancements in radioisotope production in decades. .

。

“Nusano is making generational leaps forward in physics,” said Lowe. “These advances will help our customers build robust supply chains and support improvements in quality of life for people around the world.”

洛伊说：“努萨诺在物理学上取得了一代又一代的飞跃。”。“这些进步将帮助我们的客户建立强大的供应链，并支持改善世界各地人民的生活质量。”

About Nusano

关于努萨诺

Nusano is a privately held physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, and to serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services.

。

Driven by the company’s proprietary ion source, the Nusano production platform will generate radioisotopes in volumes and varieties exceeding other production methods. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries.

在该公司专有离子源的驱动下，Nusano生产平台将产生超过其他生产方法的放射性同位素的数量和种类。努萨诺的突破性技术有望帮助对抗癌症，并实现跨多个行业的创新。